Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.35 -2.9%	$1.29	$1.05 ▼ $10.16	$42.47M	1.65	257,006 shs	213,026 shs
CALC CalciMedica	$2.91 +11.5%	$2.36	$1.42 ▼ $5.97	$40.66M	1.33	104,670 shs	28,763 shs
CUBT Curative Biotechnology	$0.01 +2.0%	$0.01	$0.00 ▼ $0.03	$10.33M	0.2	116,850 shs	13,300 shs
MRMD MariMed	$0.11 -15.4%	$0.09	$0.07 ▼ $0.26	$42.95M	3.02	918,516 shs	2.79 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	-2.88%	+8.87%	+3.85%	+17.39%	-80.77%
CALC CalciMedica	+11.49%	+6.20%	+33.49%	+45.50%	-35.76%
CUBT Curative Biotechnology	+2.00%	+6.25%	-4.67%	-12.07%	-40.70%
MRMD MariMed	-15.38%	+12.82%	+14.11%	+37.84%	-60.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	2.99 of 5 stars	3.5	3.0	0.0	0.0	2.4	2.5	0.6
CALC CalciMedica	3.3938 of 5 stars	3.5	5.0	0.0	0.0	2.4	3.3	0.0
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	1.3548 of 5 stars	0.0	5.0	0.0	0.0	2.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.57	1,201.59% Upside
CALC CalciMedica	3.00	Buy	$16.00	449.83% Upside
CUBT Curative Biotechnology	0.00	N/A	N/A	N/A
MRMD MariMed	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest CUBT, ACRV, CALC, and MRMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/14/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$9.00 ➝ $8.00
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$4.55 per share	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	$0.44 per share	N/A
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	$157.96M	0.27	$0.02 per share	5.10	$0.15 per share	0.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$80.56M	-$2.25	N/A	N/A	N/A	N/A	-50.78%	-46.08%	N/A
CALC CalciMedica	-$13.70M	-$1.60	N/A	N/A	N/A	N/A	-206.51%	-103.81%	N/A
CUBT Curative Biotechnology	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	-$12.16M	-$0.03	N/A	∞	N/A	-10.14%	-10.52%	-3.10%	N/A

Latest CUBT, ACRV, CALC, and MRMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2025	Q2 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.55	+$0.02	-$0.55	N/A	N/A
8/12/2025	Q2 2025	CALC CalciMedica	-$0.40	-$0.40	N/A	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
CALC CalciMedica	N/A	N/A	N/A	N/A	N/A
CUBT Curative Biotechnology	N/A	N/A	N/A	N/A	N/A
MRMD MariMed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	10.31	11.17
CALC CalciMedica	1.39	5.45	5.66
CUBT Curative Biotechnology	N/A	N/A	N/A
MRMD MariMed	1.25	1.12	0.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
CALC CalciMedica	N/A
CUBT Curative Biotechnology	N/A
MRMD MariMed	0.18%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
CALC CalciMedica	41.55%
CUBT Curative Biotechnology	N/A
MRMD MariMed	18.99%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.46 million	27.71 million	Not Optionable
CALC CalciMedica	30	13.97 million	8.17 million	No Data
CUBT Curative Biotechnology	4	1.01 billion	N/A	Not Optionable
MRMD MariMed	260	390.43 million	316.29 million	Not Optionable

CUBT, ACRV, CALC, and MRMD Headlines

Recent News About These Companies

Noble Financial Has Bullish Outlook for MariMed Q3 Earnings

August 16 at 2:47 AM | americanbankingnews.com

Despite Fast-paced Momentum, MariMed Inc. (MRMD) Is Still a Bargain Stock

August 14 at 9:50 AM | zacks.com

4 Medical Product Stocks to Watch From a Challenging Industry

August 14 at 9:36 AM | zacks.com

MariMed Earnings Call: Growth Amidst Challenges

August 13 at 2:46 AM | msn.com

MariMed Inc. (MRMD) Q2 2025 Earnings Call Transcript

August 7, 2025 | seekingalpha.com

MariMed (MRMD) Q2 EPS Jumps to Positive

August 6, 2025 | fool.com

MariMed Inc. (MRMD) Reports Break-Even Earnings for Q2

August 6, 2025 | zacks.com

MariMed Reports Second Quarter 2025 Earnings

August 6, 2025 | globenewswire.com

MariMed’s Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT Holdings

July 31, 2025 | finance.yahoo.com

MariMed's Products to Enter Pennsylvania Market Through a Management Services and Licensing Agreement with TILT Holdings

July 31, 2025 | globenewswire.com

CORRECTION -- MariMed Expands Access to Top-Selling Betty’s Eddies Brand in Maine

July 14, 2025 | uk.finance.yahoo.com

MariMed Expands Access to Top-Selling Betty’s Eddies Brand in Maine

July 14, 2025 | finance.yahoo.com

CORRECTION -- MariMed Expands Access to Top-Selling Betty's Eddies Brand in Maine

July 14, 2025 | globenewswire.com

MariMed Expands Access to Top-Selling Betty's Eddies Brand in Maine

July 14, 2025 | globenewswire.com

MariMed Expands Access to Top-Selling Betty's Eddies Brand in Maine

July 14, 2025 | globenewswire.com

MariMed Announces Second Quarter 2025 Earnings Date

July 8, 2025 | globenewswire.com

MariMed Statement Regarding the Commencement of Adult-Use Cannabis Sales in Delaware on August 1st

July 1, 2025 | globenewswire.com

MariMed Inc. (MRMD) Latest Stock News & Headlines - Yahoo Finance

June 24, 2025 | finance.yahoo.com

MariMed’s Premium Nature’s Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDose

May 29, 2025 | uk.finance.yahoo.com

MariMed's Premium Nature's Heritage Brand Enters Functional Mushroom Market Launching Plant-Based MycroDose

May 29, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CUBT, ACRV, CALC, and MRMD Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.35 -0.04 (-2.88%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.03 (+2.22%)

As of 08/15/2025 07:50 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

CalciMedica NASDAQ:CALC

$2.91 +0.30 (+11.49%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$2.88 -0.03 (-1.03%)

As of 08/15/2025 07:11 PM Eastern

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Curative Biotechnology OTCMKTS:CUBT

$0.01 +0.00 (+2.00%)

As of 08/15/2025 10:27 AM Eastern

Curative Biotechnology, Inc., a development-stage biomedical company, focuses on novel treatments for rare diseases. The company focuses on therapies with potentially accelerated development paths as a result of the disease, the nature of the therapeutic itself, or the stage of clinical development. Its pipeline candidates include CURB906, an antibody-drug conjugate for targeting CD56 positive brain tumors; and IMT504, a novel immune therapy to treat rabies. The company has an agreement with Mid-Atlantic BioTherapeutics, Inc. to develop the COVID-19 vaccine. Curative Biotechnology, Inc. was founded in 1995 and is based in Boca Raton, Florida.

MariMed OTCMKTS:MRMD

$0.11 -0.02 (-15.38%)

As of 08/15/2025 03:58 PM Eastern

MariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time